Sutro Biopharma, Inc. (STRO)

Sutro Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	153.73	67.77	61.88	42.72	42.74
Revenue Growth (YoY)	126.84%	9.52%	44.84%	-0.03%	11.24%
Gross Profit	153.73	67.77	61.88	42.72	42.74
Selling, General & Admin	62.58	59.54	56	36.82	32.59
Research & Development	180.43	137.17	104.4	76.96	65.61
Operating Expenses	243.01	196.72	160.4	113.78	98.2
Operating Income	-89.28	-128.94	-98.52	-71.06	-55.47
Interest Expense / Income	11.18	3.35	3.14	3.97	4.35
Other Expense / Income	-11.86	-15.59	3.88	-43.01	-4.07
Pretax Income	-88.6	-116.7	-105.54	-32.03	-55.74
Income Tax	18.19	2.5	0	0.1	0
Net Income	-106.79	-119.2	-105.54	-32.13	-55.74
Shares Outstanding (Basic)	60	51	46	33	23
Shares Outstanding (Diluted)	60	51	46	33	23
Shares Change	18.57%	10.02%	41.58%	41.88%	298.66%
EPS (Basic)	-1.78	-2.35	-2.29	-0.99	-2.43
EPS (Diluted)	-1.78	-2.35	-2.29	-0.99	-2.43
Free Cash Flow	-115.93	-4.31	-97	-74.93	-68.5
Free Cash Flow Per Share	-1.93	-0.09	-2.10	-2.30	-2.98
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-58.07%	-190.26%	-159.22%	-166.32%	-129.79%
Profit Margin	-69.47%	-175.89%	-170.55%	-75.20%	-130.44%
Free Cash Flow Margin	-75.41%	-6.36%	-156.76%	-175.39%	-160.30%
EBITDA	-66.98	-105.07	-92.63	-23.75	-46.62
EBITDA Margin	-43.57%	-155.03%	-149.69%	-55.60%	-109.08%
Depreciation & Amortization	10.44	8.29	9.77	4.3	4.78
EBIT	-77.42	-113.36	-102.4	-28.05	-51.39
EBIT Margin	-50.36%	-167.26%	-165.48%	-65.66%	-120.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).